ARKG Holdings of Vertex Pharmaceuticals (VRTX) - Updated Daily
TherapeuticsGene TherapyGenomicsCRSPR Gene Editing
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 1.81% | $83.35b |
| 🏋🏿♂️Weight Rank In ARKG | 🌏Country |
| 22 | 🇺🇸United States |
| 🏋️♀️Weight Rank Across All Funds | 💳ARK Estimated Cost Average |
| 47 | $225.49 |
| 🎫ARK Ownership Percent | |
| 0.04% | |
| Description | |
|---|---|
| vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. we discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (cf), a rare, life-threatening genetic disease. in addition to clinical development programs in cf, vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. founded in 1989 in cambridge, massachusetts, our corporate headquarters is now located in boston’s innovation district, and our international headquarters is in london, united kingdom. we currently employ 2,100 people in the united states, europe, canada and australia with nearly two-thirds of our staff dedicated to research and development. vertex is consistently recognized as one of the industry’s top places to work by science magazine, the boston globe, boston business journal and the san diego business jou | |
| Website | |
| vrtx.com |
Other ETFs That Hold VRTX
Research Notes and Commentary for VRTX
No Research Notes Found for VRTX